Gut microbiota: Unseen conductor of polyherbal efficacy in diabetic neuropathy

Abstract

The recent study provides compelling evidence for the neuroprotective effects of a polyherbal extract (PHE) in a rat model of diabetic neuropathy (DN). While the authors demonstrate significant improvements in metabolic, oxidative, and inflammatory parameters, this review posits that these downstream effects are likely orchestrated by a crucial upstream mechanism: The modulation of the gut microbiota. We argue that DN is intrinsically linked to gut dysbiosis, which promotes a “leaky gut”, systemic inflammation, and a deficit in neuroprotective microbial metabolites like short-chain fatty acids. The complex, poorly absorbed components of the PHE likely act as prebiotics, restoring microbial homeostasis. This single action can mechanistically explain the observed systemic benefits from reduced inflammation to improved neurotrophic support. Recognizing the gut microbiota as the central mediator bridges the multi-component nature of traditional herbal medicine with the complex, multi-system pathology of DN, paving the way for novel, microbiome-targeted therapeutic strategies.

Key Words: Diabetic neuropathy; Gut microbiota; Polyherbal formulation; Prebiotics; Short-chain fatty acids; Inflammation; Traditional medicine

Core Tip: This review proposes a gut-centric theoretical model to explain the broad therapeutic effects of a polyherbal extract (PHE) against diabetic neuropathy. We hypothesize that the PHE acts primarily by remodeling the gut microbiota. This single action restoring a healthy gut ecosystem can mechanistically account for the observed systemic reductions in inflammation, oxidative stress, and metabolic dysfunction. This perspective reframes traditional herbal medicine as a form of ecological intervention, highlighting the gut microbiome as a pivotal and unifying target for treating complex, multi-system diseases.

INTRODUCTION

The global landscape of chronic disease is dominated by diabetes mellitus, a metabolic disorder whose prevalence continues to escalate unabated[1]. Among its myriad complications, diabetic neuropathy (DN) stands out as one of the most common and debilitating, affecting up to half of all individuals with diabetes[2]. It manifests as a progressive loss of nerve fibers, leading to a devastating spectrum of clinical outcomes, from intractable neuropathic pain and sensory deficits to motor dysfunction and autonomic instability[2,3]. This condition not only severely compromises patients’ quality of life but also serves as a primary precursor to diabetic foot ulcers and subsequent lower-limb amputations[3].

Despite decades of research, the therapeutic armamentarium for DN remains disappointingly limited. Current pharmacological interventions are largely palliative, focusing on symptomatic pain management through anticonvulsants, antidepressants, and opioids[3]. While these agents can provide some relief, they are often associated with significant side effects, limited efficacy, and a failure to address or reverse the underlying neurodegenerative processes[4]. This profound unmet clinical need has catalyzed a paradigm shift in therapeutic exploration, turning attention towards integrative and traditional medical systems that have long championed the use of multi-component, multi-target interventions[5].

Polyherbal extract (PHE), a cornerstone of systems like traditional Chinese medicine and ayurveda, are emblematic of this approach. They are predicated on the principle of synergy, where the combined action of multiple botanical constituents achieves a therapeutic effect greater than the sum of their individual parts[6]. In a recent, exemplary study published in the World Journal of Diabetes, Kausar et al[7] provide robust preclinical validation for this very concept. Their research meticulously demonstrated that a PHE composed of Citrullus colocynthis, Curcuma longa, and Myristica fragrans conferred significant neuroprotection in a streptozotocin-induced diabetic rat model[7]. The authors presented a comprehensive body of evidence showing the PHE’s capacity to normalize hyperglycemia and dyslipidemia, powerfully augment endogenous antioxidant defenses, suppress key pro-inflammatory cytokines, and restore levels of critical neurotrophic factors[7].

These findings are both promising and mechanistically intriguing. They highlight a potential therapeutic candidate that simultaneously targets multiple pathological axes of DN. However, they also prompt a deeper, more fundamental question: How can a single orally administered formulation orchestrate such a diverse and systemic array of beneficial effects? The conventional explanation would focus on the absorption of various bioactive compounds and their subsequent actions on different target tissues. While this is undoubtedly part of the story, this editorial puts forth a unifying hypothesis: That the primary site of action for this complex herbal mixture is the gut, and its principal mechanism is the modulation of the gut microbiota. We will argue, based on logical reasoning and existing literature, that the gut microbiota is the “unseen conductor” of this polyherbal symphony, serving as the central hub that translates the chemical complexity of the PHE into a coordinated, systemic, and ultimately neuroprotective host response in this theoretical model.

THE INTRICATE PATHOPHYSIOLOGY OF DN: A MULTI-SYSTEM FAILURE

To appreciate the potential role of the gut microbiota, it is first essential to understand the complex and interconnected pathways that drive nerve damage in diabetes. DN is not the result of a single molecular defect but rather a catastrophic failure across multiple physiological systems, primarily triggered by chronic hyperglycemia.

The hyperglycemic cascade: Fueling the fire

Chronic exposure to high glucose levels initiates a cascade of detrimental metabolic events within neural and vascular cells[8]. A key pathway is the polyol pathway, where the enzyme aldose reductase converts excess glucose into sorbitol[9]. The accumulation of sorbitol creates osmotic stress within cells, while the process itself consumes nicotinamide adenine dinucleotide phosphate hydrogen (NADPH), a crucial cofactor for the antioxidant enzyme glutathione (GSH) reductase[10]. This depletes the cell’s primary antioxidant, reduced GSH, rendering it vulnerable to oxidative damage. Concurrently, hyperglycemia drives the non-enzymatic glycation of proteins and lipids, leading to the formation of advanced glycation end-products (AGEs)[11]. AGEs can directly damage nerve structures and, by binding to their receptor (RAGE), trigger a pro-inflammatory and pro-oxidant signaling cascade[12]. A pathway strongly implicated in the microvascular complications of diabetes, including neuropathy[13]. Finally, hyperglycemia activates the protein kinase C pathway, which contributes to vascular dysfunction, increased vascular permeability, and altered nerve blood flow, ultimately leading to nerve ischemia[14], further compromising neuronal health by creating a hypoxic environment[15].

Oxidative stress as a central hub

Nearly all pathways of hyperglycemic damage converge on the generation of oxidative stress[16]. The overproduction of reactive oxygen species and reactive nitrogen species from sources like mitochondrial electron transport chain dysfunction[17], NADPH oxidases, and the autoxidation of glucose overwhelms the cell’s endogenous antioxidant capacity[18-20]. Specifically, mitochondrial dysfunction is now considered a key initiator of oxidative stress in diabetic complications, leading to a self-perpetuating cycle of damage[21]. This state of oxidative stress leads to widespread damage of cellular components, including lipid peroxidation of cell membranes (as measured by malondialdehyde, or MDA, levels), protein carbonylation, and DNA damage[16]. In the context of DN, Schwann cells and neurons are particularly susceptible, leading to demyelination, axonal degeneration, and eventual neuronal apoptosis[22]. The findings of Kausar et al[7], showing a marked reduction in MDA and restoration of GSH, superoxide dismutase (SOD), and catalase (CAT) activities by the PHE, directly address this central pathological hub.

Chronic inflammation and immune dysregulation

The neurodegenerative process in DN is actively sustained by a state of chronic, low-grade inflammation, often termed “metaflammation”[23]. The signaling cascades initiated by AGE-RAGE interaction and oxidative stress lead to the activation of the master inflammatory transcription factor, nuclear factor-kappa B (NF-κB)[24]. Activated NF-κB translocates to the nucleus and drives the expression of numerous pro-inflammatory genes, including those for cytokines like tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β)[25]. These cytokines perpetuate a vicious cycle of inflammation and oxidative stress, recruit immune cells like macrophages to the nerve tissue, and can directly induce neuronal apoptosis[26]. This process, often termed neuroinflammation, involves not only immune cells but also the activation of glial cells (Schwann cells, satellite glial cells) within the peripheral nervous system, which actively contribute to the pathogenesis of neuropathic pain[27]. The PHE’s ability to significantly lower systemic levels of TNF-α and IL-1β, as shown by Kausar et al[7], points to a potent anti-inflammatory mechanism of action.

Impaired neurotrophic support and vascular dysfunction

Peripheral neurons rely on a constant supply of neurotrophic factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), for their survival, growth, and maintenance[28,29]. In diabetes, the expression and transport of these vital factors are significantly impaired, contributing to the “dying back” axonopathy characteristic of DN[30]. This impairment can result from reduced gene expression, deficits in axonal transport machinery, and increased degradation of neurotrophic factors in the hyperglycemic environment[31]. Furthermore, the microvasculature that supplies nerves, the vasa nervorum, becomes dysfunctional. Endothelial dysfunction, basement membrane thickening, and impaired vasodilation lead to chronic nerve hypoxia and ischemia, further exacerbating the metabolic and oxidative stress on the neurons and Schwann cells[32].

THE GUT MICROBIOTA: AN OVERLOOKED PROTAGONIST IN DIABETES AND NEUROPATHY

For decades, the gut was viewed primarily as an organ of digestion and absorption. We now understand that it houses a complex and dynamic ecosystem the gut microbiota that functions as a virtual organ, profoundly influencing host physiology. The link between the gut microbiota and diabetes is now firmly established, and emerging evidence strongly implicates it as a key player in the pathogenesis of DN.

Defining gut eubiosis vs dysbiosis

A healthy gut microbiome, or “eubiosis”, is characterized by high microbial diversity and a balanced community dominated by beneficial, commensal bacteria[33]. In contrast, “dysbiosis”, a hallmark of type 2 diabetes, is defined by reduced diversity, an altered community structure, and a functional imbalance[34]. This typically involves a depletion of butyrate-producing bacteria from the Firmicutes phylum (e.g., Faecalibacterium prausnitzii, Roseburia) and mucin-degrading bacteria like Akkermansia muciniphila, coupled with an expansion of opportunistic pathogens and pro-inflammatory pathobionts[35].

Mechanism 1: The leaky gut and metabolic endotoxemia

One of the most critical consequences of diabetic dysbiosis is the impairment of the intestinal barrier function. A healthy microbiota fortifies this barrier by fermenting dietary fiber into short-chain fatty acids (SCFAs), which nourish the epithelial cells (colonocytes) and promote the expression of tight junction proteins that seal the gaps between them[36]. When dysbiosis leads to a deficit in these beneficial microbes and their metabolites, the barrier becomes compromised, a condition colloquially known as “leaky gut”[37]. This increased intestinal permeability allows components of the bacterial cell wall, most notably lipopolysaccharide (LPS) from gram-negative bacteria, to translocate from the gut lumen into the systemic circulation[38]. This phenomenon, termed “metabolic endotoxemia”, is a potent trigger of systemic inflammation[38,39]. Circulating LPS binds to Toll-like receptor 4 (TLR4) on immune cells throughout the body, activating the NF-κB pathway and inducing the production of TNF-α and IL-1β[39]. This provides a direct and powerful mechanistic link between a disturbed gut environment and the chronic systemic inflammation that drives nerve damage in DN. Recent evidence suggests that this LPS-TLR4 signaling can also occur directly within the peripheral nervous system, sensitizing nociceptors and contributing to neuropathic pain[40].

Mechanism 2: The crucial role of microbial metabolites-SCFAs

SCFAs (butyrate, propionate, and acetate) are the principal metabolic output of the healthy gut microbiome. Their functions are far-reaching and directly counter the pathologies of DN. Butyrate is the preferred energy source for colonocytes, thus maintaining gut barrier integrity[41]. It is also a potent histone deacetylase inhibitor, a form of epigenetic modulation that generally suppresses inflammatory gene expression[42]. SCFAs stimulate the secretion of gut hormones like glucagon-like peptide-1 (GLP-1) from enteroendocrine cells, which enhances insulin secretion and improves glucose homeostasis[43]. Systemically, they can cross the blood-brain barrier and exert direct neuro-modulatory and anti-inflammatory effects within the central and peripheral nervous systems[44], partially by modulating the activity of microglia and astrocytes, the resident immune cells of the nervous system[45]. The depletion of SCFA production in diabetic dysbiosis therefore removes a critical layer of metabolic and immune protection, exacerbating hyperglycemia, inflammation, and neuronal vulnerability. Butyrate, in particular, has been shown to have neuroprotective effects by maintaining mitochondrial function and promoting the expression of neurotrophic factors[46].

Mechanism 3: The gut-nerve axis-a direct line of communication

The gut and the nervous system are intricately linked through the bidirectional gut-nerve axis. This communication occurs via multiple channels: (1) The vagus nerve, which provides a direct neural highway and can sense microbial metabolites[47]; (2) The systemic circulation of microbial metabolites (like SCFAs) and neurotransmitters (bacteria can produce or influence the production of gama-aminobutyric acid, serotonin, and dopamine); and (3) The modulation of the enteric nervous system[48]. Dysbiosis can disrupt this delicate signaling network, contributing to altered pain perception, a key feature of neuropathic pain, and reduced neurotrophic support[48]. Restoring a healthy microbial community can thus have direct, positive effects on neuronal function and pain modulation.

PHES AS ECOLOGICAL ENGINEERS OF THE GUT MICROBIOME

This understanding of the gut microbiota’s role in DN pathogenesis provides a powerful new lens through which to interpret the efficacy of the PHE studied by Kausar et al[7]. The key insight is the “low bioavailability paradox”: Many of the most celebrated phytochemicals, like curcumin, are very poorly absorbed in the small intestine. For years, this was seen as a major limitation. It is now becoming clear that this is, in fact, a central feature of their mechanism. Their poor absorption ensures that they reach the colon in high concentrations, where they can directly interact with and shape the gut microbial community.

Deconstructing the Kausar et al[7] PHE: A mechanistic deep dive

Each component of the studied PHE possesses properties that make it an ideal candidate for a microbiome-modulating agent. The key bioactive compounds from each plant source, along with their hypothesized direct actions on the microbiota and subsequent systemic effects relevant to DN, are summarized in Table 1.

Table 1 Key bioactive compounds in the polyherbal extract and their hypothesized microbiome-mediated mechanisms in diabetic neuropathy.

Plant source	Key bioactive compounds	Direct action on microbiota	Microbiome-mediated systemic effects	Relevance to diabetic neuropathy
Curcuma longa (turmeric)	Curcuminoids (e.g., curcumin)	Prebiotic effect: Promotes growth of Bifidobacterium, Lactobacillus[49]. Antimicrobial: Inhibits growth of pathogenic taxa. Biotransformation: Gut microbes convert it to more bioactive metabolites (e.g., tetrahydrocurcumin)[49]	Anti-inflammatory: Reduced LPS translocation and microbial metabolism to anti-inflammatory compounds. Improved metabolism: Enhanced gut hormone secretion	Directly counters the chronic inflammation (TNF-α decrease, IL-1β decrease) and oxidative stress that drive nerve damage
Citrullus colocynthis (bitter apple)	Cucurbitacins, flavonoids, polysaccharides (fiber)	Selective fermentation: Serves as a primary substrate for SCFA-producing bacteria (e.g., Faecalibacterium, Roseburia)[52]. Diversity enhancer: Provides diverse nutrients for a wide range of commensal microbes	Barrier fortification: Increased butyrate production nourishes colonocytes, strengthening tight junctions. Metabolic regulation: Increased SCFAs improve glucose homeostasis and insulin sensitivity via GLP-1	Addresses metabolic dysregulation and restores intestinal barrier integrity, reducing the primary inflammatory trigger
Myristica fragrans (nutmeg)	Myristicin, eugenol, phenolic compounds	Selective antimicrobial: Suppresses the overgrowth of specific pathobionts without eliminating beneficial commensals[54]. Ecosystem remodeling: Creates an ecological niche for beneficial bacteria to repopulate and thrive	Reduced pathobiont load: Decreased production of pro-inflammatory bacterial products (e.g., hydrogen sulfide from sulfate-reducing bacteria). Neurotransmitter modulation: Influences microbial production of neuroactive compounds	Helps rebalance the dysbiotic ecosystem, potentially alleviating neuropathic pain through modulation of the gut-nerve axis

SCFA: Short-chain fatty acid; LPS: Lipopolysaccharide; GLP-1: Glucagon-like peptide-1; TNF: Tumor necrosis factor; IL: Interleukin.

Curcuma longa (turmeric): Its primary active compound, curcumin, has a profound and bidirectional relationship with the gut microbiota. It acts as a prebiotic, promoting the growth of beneficial taxa like Bifidobacterium and Lactobacillus while exhibiting antimicrobial activity against potential pathogens[49]. These actions can help rebalance the Firmicutes/Bacteroidetes ratio often disrupted in diabetes and other metabolic diseases[50]. In turn, the gut microbiota metabolizes curcumin into more soluble and often more bioactive forms, such as tetrahydrocurcumin, enhancing its systemic effects[49], a process known as microbial biotransformation which is critical for the efficacy of many polyphenols[51].

Citrullus colocynthis (bitter apple): This plant is a rich source of complex carbohydrates (dietary fibers) and flavonoids. These molecules are quintessential prebiotics. They resist digestion in the upper gastrointestinal tract and are selectively fermented by SCFA-producing bacteria in the colon, directly fueling the production of beneficial metabolites like butyrate[52]. By nourishing keystone species like Faecalibacterium prausnitzii, a major butyrate producer, this component can directly support colonocyte health and fortify the gut barrier. The role of such dietary fibers in maintaining gut barrier integrity is a cornerstone of microbiome-based therapeutic strategies[53].

Myristica fragrans (nutmeg): Nutmeg contains a variety of phenolic compounds and essential oils with known selective antimicrobial properties. In a dysbiotic gut, these compounds can act to “weed out” overgrown pathobionts, creating an ecological niche that allows for the re-establishment and growth of beneficial commensal bacteria[54], including mucin-specialists like Akkermansia muciniphila, which are crucial for maintaining the protective mucus layer of the intestine and have been shown to be depleted in diabetic individuals[55].

Synergy in action: A multi-pronged ecological intervention

The true power of the PHE likely lies in the synergy of these actions. It doesn’t just provide a single substrate; it engineers the entire ecosystem. Citrullus colocynthis provides the “fertilizer” (fiber) for beneficial microbes[52]. Curcuma longa provides both fertilizer (prebiotic effects) and a “growth promoter” (bioactive polyphenols)[49]. Myristica fragrans acts as a “selective herbicide”, helping to control the overgrowth of undesirable species[54]. This multi-pronged approach is far more likely to achieve a stable and resilient shift back towards eubiosis than a single-component intervention. This concept of synergistic action is a fundamental principle in traditional herbal medicine and is now being explored through the lens of network pharmacology and systems biology[56].

Reinterpreting the Kausar et al[7] findings through the microbiome lens

Our proposed gut-centric model provides a coherent framework for understanding the specific results reported by Kausar et al[7]. The authors observed a significant reduction in the oxidative stress marker MDA and a restoration of endogenous antioxidants (GSH, SOD, CAT). This is highly consistent with a microbiome-mediated mechanism. By restoring gut barrier integrity, the PHE would reduce the influx of pro-inflammatory LPS, a major trigger of systemic oxidative stress. Furthermore, the increased production of SCFAs like butyrate has direct antioxidant and anti-inflammatory properties. Similarly, the observed sharp decrease in systemic inflammatory cytokines (TNF-α and IL-1β) can be directly attributed to the reduction in metabolic endotoxemia, which is a primary driver of TLR4-mediated inflammatory cascades. While the Kausar et al[7] study provides compelling downstream evidence, it did not include direct measurements of gut microbiota composition, intestinal permeability, or SCFA levels. This represents a critical knowledge gap and a clear direction for future research to validate this hypothesis.

Kausar et al[7] study data and hypothesis compatibility

Kausar et al[7] reported significant reductions in MDA and increases in GSH/SOD/CAT in PHE-treated rats, which is highly compatible with our gut microbiota hypothesis. The observed antioxidant and anti-inflammatory effects can be mechanistically explained by the restoration of gut barrier function and increased SCFA production mediated by PHE-induced microbiota remodeling. However, the original study did not measure gut microbiota composition, SCFA levels, or intestinal permeability biomarkers this is a critical knowledge gap and the key future research direction to validate our hypothesis. Future studies should incorporate these measurements to establish a direct causal link between PHE-induced microbiota changes and neuroprotective effects in DN.

SYNTHESIZING THE EVIDENCE: A UNIFIED GUT-CENTRIC MODEL FOR PHE'S NEUROPROTECTION

We can now construct a unified model that traces the therapeutic effects of the PHE from oral administration to neuroprotection, with the gut microbiota at its core (Figure 1). The pathophysiology of DN is driven by a vicious cycle initiated by hyperglycemia (panel A). This leads to gut dysbiosis, characterized by a loss of beneficial bacteria and an increase in pathobionts[34,35]. The compromised microbiota impairs the intestinal barrier (“leaky gut”), allowing LPS translocation, which triggers systemic inflammation via TLR4 activation (metabolic endotoxemia)[38,39]. Concurrently, a deficit in SCFA production exacerbates metabolic dysregulation and removes crucial anti-inflammatory and neurotrophic support[41,44]. These systemic insults oxidative stress, inflammation, and reduced neurotrophic factors (BDNF/NGF) converge to cause nerve damage. The PHE acts as a powerful ecological intervention (panel B). Its complex, poorly absorbed components serve as prebiotics, remodeling the gut microbiota back towards a healthy, eubiotic state. This single action restores the intestinal barrier, reduces LPS-driven inflammation, boosts SCFA production, and enhances gut hormone signaling (e.g., GLP-1)[43]. The systemic consequences are a reduction in oxidative stress and inflammation, improved metabolic control, and restored neurotrophic support, which collectively create a permissive environment for nerve repair and functional recovery, thus ameliorating DN. This model is constructed based on the pathological and intervention mechanisms reported in previous studies[34,38,48].

Figure 1 The gut microbiota as the central mediator of polyherbal neuroprotection in diabetic neuropathy. DN: Diabetic neuropathy; SCFA: Short-chain fatty acid; LPS: Lipopolysaccharide; TNF: Tumor necrosis factor; IL: Interleukin.

Oral ingestion and colonic delivery

The PHE is ingested. Its complex, low-bioavailability components transit to the colon.

Microbiome remodeling

In the colon, the PHE’s synergistic components selectively nourish beneficial bacteria and suppress pathobionts. This reverses the diabetic dysbiosis, increasing microbial diversity and restoring the abundance of SCFA producers.

Restoration of gut barrier integrity

The renewed production of butyrate and other beneficial metabolites strengthens the intestinal barrier, sealing the tight junctions.

Reduction of systemic inflammation

The restored barrier function drastically reduces the translocation of LPS into the bloodstream. This drop in metabolic endotoxemia leads to decreased TLR4 activation and a subsequent reduction in the systemic production of TNF-α and IL-1β, as observed by Kausar et al[7].

Improved metabolic control and antioxidant status

The increase in SCFAs enhances GLP-1 secretion, improving glucose control and insulin sensitivity. The systemic antioxidant and anti-inflammatory properties of SCFAs and other microbial metabolites help to quench the oxidative fire, reducing MDA levels and restoring the body’s capacity to produce GSH, SOD, and CAT.

Enhanced neurotrophic support and neuromodulation

A healthy gut-nerve axis, supported by eubiosis and ample SCFAs, promotes the systemic and local production of neurotrophic factors like BDNF and NGF. This provides direct support for neuronal survival and regeneration.

Neuroprotection and functional recovery

The culmination of these systemic improvements reduced inflammation, quenched oxidative stress, better metabolic control, and enhanced neurotrophic support alleviates the multiple pathological pressures on the peripheral nerves. This halts the neurodegenerative process and allows for repair and regeneration, leading to the observed improvements in nerve histology and behavioral function. This gut-centric model provides a single, coherent explanation for the entire suite of beneficial outcomes reported in the Kausar et al’s study[7], elegantly connecting a local action in the gut to a systemic and neuroprotective effect.

FUTURE PERSPECTIVES AND TRANSLATIONAL CHALLENGES

While this model is compelling, it remains a hypothesis that requires rigorous scientific validation. The path forward involves several key research directions and the navigation of significant translational hurdles.

From correlation to causation

To prove that the microbiota is a necessary mediator of the PHE’s effects, future preclinical studies must incorporate more advanced designs. It is important to acknowledge that direct absorption of some bioactive compounds may also contribute to the therapeutic effect, working in synergy with microbiome-mediated pathways. Fecal microbiota transplantation experiments, where the microbiota from PHE-treated diabetic rats is transferred to naive diabetic rats, would be a powerful tool. The success of fecal microbiota transplantation in various metabolic and inflammatory conditions provides a strong rationale for its use as a mechanistic tool in this context[57]. If the recipient animals show signs of neuroprotection, it would provide strong evidence for the microbiota’s causal role. Studies using germ-free or antibiotic-treated animals could further elucidate the necessity of the gut microbiome for the PHE’s efficacy. Furthermore, comparing the efficacy of oral vs parenteral administration of the PHE could help distinguish between gut-dependent and gut-independent effects.

The power of multi-omics

A deep understanding of the mechanism requires a multi-omics approach. Future studies should integrate shotgun metagenomics (to see which microbes are present and what genes they have), meta-transcriptomics (which genes are active), metabolomics (what metabolites are being produced), and host transcriptomics (how host tissues respond). Such an integrative approach has been pivotal in uncovering novel host-microbe interactions in other complex diseases and is essential for moving beyond simple associative studies[58]. This will allow researchers to build a comprehensive map of the entire PHE-microbiota-host interaction network, identifying specific bacterial taxa, metabolic pathways, and host signaling cascades that are critical for the therapeutic effect.

Overcoming clinical hurdles

Translating this promising preclinical work into a viable clinical therapy for DN is a major challenge.

Standardization: Herbal products are notoriously variable. Rigorous standardization of the PHE is paramount. This requires advanced quality control measures, including high-performance liquid chromatography or mass spectrometry fingerprinting to ensure batch-to-batch consistency in the chemical profile. In addition, bioassays (e.g., in vitro gut fermentation models) are crucial to ensure that different batches of PHE have consistent microbial regulatory activity.

Personalization: The human gut microbiome is highly individualized. This means a “one-size-fits-all” PHE might not work for everyone. Future clinical trials should incorporate baseline microbiome analysis to stratify patients and identify potential “responders” and “non-responders”. This aligns with the broader movement towards personalized or precision nutrition, where interventions are tailored based on an individual’s unique biological makeup, including their microbiome[59]. Crucially, these studies must also account for potent microbiome confounders like baseline diet and medication history (especially antibiotics and proton pump inhibitors) to accurately predict treatment response.

Clinical trial design: Large-scale, double-blind, placebo-controlled clinical trials are the gold standard and are urgently needed. These trials should not only measure standard clinical endpoints for DN (e.g., nerve conduction velocity, pain scores, quality of life) but also incorporate microbiome and metabolome analyses as secondary endpoints to validate the proposed mechanism in humans. Integrating these biomarker analyses into clinical trials is crucial for mechanism-based drug development and for identifying patient subgroups who are most likely to benefit[60].

CONCLUSION

The study by Kausar et al[7] provides an outstanding demonstration of the therapeutic potential of a well-chosen polyherbal formulation for DN. It highlights a path away from single-target palliation towards a multi-system, restorative approach. By reinterpreting their findings through the lens of modern microbiome science, we can appreciate a deeper, more profound mechanism at play. The gut microbiota, far from being a passive bystander, appears to be the central mediator, the unseen conductor that translates the ecological intervention of the PHE into a cascade of systemic benefits that culminate in neuroprotection. This gut-centric perspective does more than just add another layer of complexity; it provides a unifying framework that connects traditional herbal wisdom with cutting-edge molecular biology. It suggests that for chronic, multi-system diseases like DN, the most effective therapies may not be those that target a single receptor, but those that restore homeostasis to a critical ecosystem. The journey from this promising preclinical insight to a validated clinical therapy will be long and challenging, but it is a path that holds immense promise for the millions of individuals worldwide burdened by this devastating complication.